We believe every clinical trial should be run twice — first in silico.
Boost the world's transition to accessible therapies.
A team of life scientists, engineers, and AI researchers — united by a single conviction.
We are a team of life sciences, cybersecurity, and digital innovation experts united by a single conviction: drug development must change. The cost and time of taking a new medical product through clinical trials has become unsustainable — and in silico technology is the lever that moves it.
Through our computational modeling and simulation platform, we help pharmaceutical companies, medical device makers, and research institutions reduce clinical trial risk, accelerate regulatory timelines, and bring accessible treatments to patients faster.
We are an Equal Opportunity Employer — a team of 24 across 2 continents representing 6 nationalities, with 50% female employees and a culture built on scientific rigor and radical transparency.
The team behind the science.
Our broader team of 19 brings together computational biologists, pharmacometricians, software engineers, AI researchers, and regulatory scientists from six countries. Over a third hold PhDs or MDs. All of them share the same conviction: that in silico technology will change how medicine is developed — and that it should happen now.
Committed to SDG 3 and SDG 9.
Our platform reduces the cost and risk of drug development, enabling researchers to bring safer, more accessible medicines to patients worldwide — regardless of geography or income.
We are building resilient digital infrastructure for life sciences, fostering innovation in AI-driven modeling and simulation that redefines how clinical research is designed and executed.
34123 Trieste
20154 Milan
Wilmington, DE 19801